These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18435811)

  • 41. The use of the decision tree technique and image cytometry to characterize aggressiveness in World Health Organization (WHO) grade II superficial transitional cell carcinomas of the bladder.
    Decaestecker C; van Velthoven R; Petein M; Janssen T; Salmon I; Pasteels JL; van Ham P; Schulman C; Kiss R
    J Pathol; 1996 Mar; 178(3):274-83. PubMed ID: 8778332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
    Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
    Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Micropapillary pattern in urothelial carcinoma: a clinicopathological analysis.
    Alkibay T; Sözen S; Gürocak S; Işik Gönül I; Poyraz A; Ure I
    Urol Int; 2009; 83(3):300-5. PubMed ID: 19829030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis.
    Canter D; Guzzo T; Resnick M; Magerfleisch L; Sonnad S; Bergey M; Tomazewski J; Vaughn D; Van Arsdalen K; Malkowicz B
    BJU Int; 2008 Sep; 102(8):952-7. PubMed ID: 18485042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system.
    Nishiyama N; Kitamura H; Maeda T; Takahashi S; Masumori N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2013 Nov; 43(11):1124-31. PubMed ID: 23980236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prognostic significance of pathologic stage T0 on organ-confined bladder transitional cell carcinoma following radical cystectomy.
    Cho KS; Seo JW; Park SY; Cho NH; Choi YD; Yang SC; Hong SJ
    Urol Int; 2008; 81(4):394-8. PubMed ID: 19077398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differences in tumor characteristics and prognosis in newly diagnosed Ta, T1 urothelial carcinoma of bladder according to patient age.
    Cho KS; Hwang TK; Kim BW; Yoon DK; Chang SG; Kim SJ; Park JY; Cheon J; Sung GT; Hong SJ;
    Urology; 2009 Apr; 73(4):828-32, 832.e1. PubMed ID: 19195693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.
    van Rhijn BW; van Leenders GJ; Ooms BC; Kirkels WJ; Zlotta AR; Boevé ER; Jöbsis AC; van der Kwast TH
    Eur Urol; 2010 Jun; 57(6):1052-7. PubMed ID: 19765886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Copenhagen bladder cancer project II.
    Sørensen BL; Barlebo H; Bay-Nielsen H; Gammelgaard PA; Hvidt V; Walbom-Jørgensen S
    Dan Med Bull; 1986 Jun; 33(3):155-61. PubMed ID: 3720364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?
    Ferrone CR; Tang LH; Tomlinson J; Gonen M; Hochwald SN; Brennan MF; Klimstra DS; Allen PJ
    J Clin Oncol; 2007 Dec; 25(35):5609-15. PubMed ID: 18065733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma.
    Simone G; Papalia R; Loreto A; Leonardo C; Sentinelli S; Gallucci M
    BJU Int; 2009 Apr; 103(8):1052-7. PubMed ID: 18990140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
    Kalantari MR; Ahmadnia H
    Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases.
    Fritsche HM; Burger M; Denzinger S; Legal W; Goebell PJ; Hartmann A
    J Urol; 2008 Nov; 180(5):1923-7. PubMed ID: 18801525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
    Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
    Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems.
    Busch C; Algaba F
    Virchows Arch; 2002 Aug; 441(2):105-8. PubMed ID: 12189498
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.
    van de Putte EEF; Bosschieter J; van der Kwast TH; Bertz S; Denzinger S; Manach Q; Compérat EM; Boormans JL; Jewett MAS; Stoehr R; van Leenders GJLH; Nieuwenhuijzen JA; Zlotta AR; Hendricksen K; Rouprêt M; Otto W; Burger M; Hartmann A; van Rhijn BWG
    BJU Int; 2018 Dec; 122(6):978-985. PubMed ID: 29637669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
    Ather MH; Zaidi M
    Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up.
    Mariappan P; Fineron P; O'Donnell M; Gailer RM; Watson DJ; Smith G; Grigor KM
    World J Urol; 2021 Feb; 39(2):425-431. PubMed ID: 32266509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.